|
|
 |
|
Viewing report
|
|
|
|
Nuclear Oncology
CME Group, July 2008
Genetic alterations often indicate the risk of developing cancer and can define molecular signatures suitable for radionuclide diagnosis and therapy. Once identified, they can be targets for stable or radioactive pharmaceuticals to try to bring about complete or partial remission of the patient’s disease. This program in Nuclear Oncology covers imaging, dosimetric, and therapeutic applications of radiopharmaceuticals and metabolic imaging agents, with descriptions of how these techniques are being applied in the care of patients. The integration of imaging to personalized treatment choices is also emphasized.
Target Audience: This program will have special relevance for nuclear medicine physicians, radiologists, and radiation oncologists, and will also be useful for all who treat patients with cancer.
Learning Objectives
At the conclusion of this program, participants should be able to:
- Improve their ability to treat patients with Lymphoma
- Select appropriate therapy for a variety of tumors
- Describe particular advantages of alpha therapy
- Describe current and future directions of research
Accreditation Statement
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 9.70 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Policy on Speaker and Provider Disclosure
It is the policy of The Johns Hopkins University School of Medicine that the speaker and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). The Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made in the activity electronic syllabus. The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.
Release date: July 15, 2008
Credits expire: June 15, 2011
CME credit is obtained upon successful completion of an activity evaluation. A processing fee must accompany the completed evaluation application.
A note on the format:
DVD: Video - DVD: Includes 5 DVDs with carrying case, a comprehensive course syllabus on CD-ROM, and a program evaluation
Also available
Lynn Sage Breast Cancer Symposium
Customers who bought this item also bought
Hematology and Medical Oncology Best Practices
Personalized Medicine - Scientific and Commercial Aspects
Drug Delivery in Cancer - Technologies, Markets and Companies
Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer
Lynn Sage Breast Cancer Symposium
Dealmaking and Industry Outlook: Targeted Cancer Therapies
PET/CT and SPECT/CT To Plan and Monitor the Treatment of Cancer
Comprehensive Review of Neurology
Oncology Pipelines: Is the Future Targeted Therapy?
Cancer Vaccines and Tumor Immunity
|
|
|
|
